---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-149296"
form_type: "8-K"
ticker: "PVLA"
cik: "0001583648"
company_name: "PALVELLA THERAPEUTICS, INC."
filed_at: "2023-05-19T23:59:59+00:00"
generated_at: "2026-06-14T19:47:25.320376+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Pieris receives Nasdaq bid-price deficiency notice; 180-day cure period

## Summary
- Closing bid price below $1.00 for 30 consecutive business days triggers deficiency under Nasdaq Listing Rule 5550(a)(2).
- Company has until November 13, 2023 to regain compliance; needs $1.00+ close for 10 consecutive days.
- If not cured by initial date, may be eligible for additional 180-day period if other listing standards are met.
- Options being considered include a reverse stock split; no immediate effect on trading under symbol PIRS.

## SEC filing metadata
- accession: 0001193125-23-149296
- form_type: 8-K
- ticker: PVLA
- cik: 0001583648
- company_name: PALVELLA THERAPEUTICS, INC.
- filed_at: 2023-05-19T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1583648/000119312523149296/0001193125-23-149296-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1583648/000119312523149296/d448653d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-149296
- JSON: https://secwatch.observer/filing/0001193125-23-149296.json
- Plain text: https://secwatch.observer/filing/0001193125-23-149296.txt

## Key facts
- Listing & Compliance Notices
  PALVELLA THERAPEUTICS, INC. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).
  - Exchange: nasdaq
  - Notice: deficiency notice
  - Deficiency: minimum bid price
  - Rules: 5550(a)(2), 5810(c)(3)(A)
  source text: May 15, 2023, Pieris Pharmaceuticals, Inc. (the “Company”) received written notice (the “Notice”) from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, because the closing bid price for the Company’s common stock, par value $0.001 per share (the “Common Stock”), has fallen below $1.00 per share for 30 consecutive business days, the Company no longer meets the minimum bid price requirement for continued inclusion on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Requirement”). This Not
  evidence_url: https://www.sec.gov/Archives/edgar/data/1583648/000119312523149296/0001193125-23-149296-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.